Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 12 EP applications Marie Suzanne Westberg has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 18, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11751752

TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY

IPC classification:
A61K 31/221, A61K 31/41, A61P 9/00, A61P 9/04, A61P 9/12
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Agent:
Karen Dorothee Larbig, Novartis Pharma GmbH
Status:
EXAMINATION IN PROGRESS
EP14167842

Treating dyspnea associated with acute heart failure with H2 relaxin

IPC classification:
A61K 38/22, A61P 9/04, C07K 14/64
Agent:
Marie Suzanne Westberg, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14191582

Treatment of familial Mediterranean Fever with anti IL-1b antibodies

IPC classification:
A61K 39/395, A61P 19/02, A61P 37/00, C07K 16/24
Applicant:
Novartis AG
Agent:
Marie Suzanne Westberg, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13745552

TREATING INFLAMMATION USING SERELAXIN

IPC classification:
A61K 38/00
Applicant:
Novartis AG
Agent:
Marie Suzanne Westberg, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13798486

USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE

IPC classification:
A61K 39/395, A61P 9/00, A61P 29/00, C07K 16/24
Applicant:
Novartis AG
Agent:
Marie Suzanne Westberg, Novartis AG
Status:
EXAMINATION IN PROGRESS
EP11709841

MODULATING AQUAPORINS WITH RELAXIN

IPC classification:
A61K 38/22, A61P 7/10, A61P 7/12, A61P 15/04
Applicant:
University of Florida Research Foundation
Applicant:
University of Melbourne
Agent:
Marie Suzanne Westberg, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11758422

NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE OF NEP INHIBITORS

IPC classification:
C07C 227/18, C07C 227/20, C07C 227/22, C07C 229/30, C07C 229/34, C07C 231/10, C07C 269/06, C07C 271/22, C07D 207/24, C07D 207/267, C07D 207/27, C07D 207/277, C07D 207/33, C07D 207/38
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Agent:
Karen Dorothee Larbig, Novartis Pharma GmbH
Status:
PATENT GRANTED
EP16162699

ANTIBODY FORMULATION

IPC classification:
A61K 39/395, C07K 16/24
Applicant:
Novartis AG
Agent:
Marie Suzanne Westberg, Novartis AG
Status:
EXAMINATION REQUESTED
EP11758421

PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS

IPC classification:
C07C 269/06, C07C 271/22
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Agent:
Karen Dorothee Larbig, Novartis Pharma GmbH
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15717969

METHODS OF SELECTIVELY TREATING ASTHMA USING IL-13 ANTAGONISTS

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Marie Suzanne Westberg, Novartis AG
Status:
EXAMINATION REQUESTED
EP16174665

METHOD OF TREATING CHRONIC HEART FAILURE

IPC classification:
A61K 38/22, A61P 9/04, C07K 14/64
Agent:
Marie Suzanne Westberg, Novartis AG
Status:
Request for examination was made
EP15730858

USE OF SERELAXIN TO REDUCE GDF-15

IPC classification:
A61B 5/00, A61K 38/00, A61K 38/22, A61P 9/00, A61P 11/00
Applicant:
Novartis AG
Agent:
Marie Suzanne Westberg, Novartis Pharma AG
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature